-+ 0.00%
-+ 0.00%
-+ 0.00%

B. Riley Securities Maintains Neutral on Theravance Biopharma, Raises Price Target to $17

Benzinga·04/07/2026 16:47:05
Listen to the news
B. Riley Securities analyst Mayank Mamtani maintains Theravance Biopharma (NASDAQ:TBPH) with a Neutral and raises the price target from $14 to $17.